U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07077252) titled 'Phase I/II Study of SCTB39G in Advanced Solid Tumours' on July 11.
Brief Summary: This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39G as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
Study Start Date: July 28
Study Type: INTERVENTIONAL
Condition:
Advanced Malignant Solid Tumor
Intervention:
DRUG: SCTB39G
SCTB39G,IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Sinocelltech Ltd.
Disclaimer: Curated by HT Syndica...